: iStockAnalyst.com Symbols Feed

Seven Potential Short Stocks In Healthcare

Mon, 26 Oct 2009 13:45:00 GMT

On October 12, I wrote an article on seven bull stocks to know in healthcare (medical) sector. In the present article, I will be taking you through the seven stocks that you could profit by shorting.[More...]

21 Breakout Stocks To Watch & Using Apple LEAP Options To Generate Income

Fri, 23 Oct 2009 20:16:38 GMT

I list some stocks which moved much higher on large volume. Also, I talk about the benefits of using LEAP options versus purchasing stock.[More...]

Spectrum Pharma (NASDAQ:SPPI): Undervalued Based On Late-Stage Pipeline

Fri, 19 Jun 2009 16:45:08 GMT

With two potential approvals coming up in the next 120 days, Spectrum Pharmaceuticals (Nasdaq: SPPI) still remains a hidden gem. Investor's Business Daily bases its rankings on the relationship that one company has with other companies within the same industry. In my June 12 article, I indicated the company could likely generate $280 million in annual revenue within the next 12-18 months upon approval of both the company's cancer drugs Zevalin and Fusilev. The table below is a lis (...)[More...]

Earnings Preview for Feb 9-13 - Earnings Preview

Fri, 06 Feb 2009 18:52:00 GMT

Activision Blizzard Inc. (ATVI) could top expectations. IntercontinentalExchange, Inc. (ICE) and Terex Corporation (TEX) could miss. Though nearly 400 companies are scheduled to report, traders are going to keep a close eye on Washington. Treasury Secretary Timothy Geithner will announce a revised bank bailout plan on Monday. This plan could include the creation of a bad bank to absorb distressed debts (what TARP was[More...]

Biotech Breakout - Amylin Pharmaceuticals, Inc.

Thu, 05 Feb 2009 01:27:00 GMT

Last night we said that biotechs were poised to breakout and they delivered. AMLN, ALXN, [More...]

Small Cap, High Growth Healthcare Trio

Wed, 28 Jan 2009 18:16:00 GMT

Jim Oberweis, Jr., money manager and editor of The Oberweis Report, is a long-standing expert in small cap, high growth growth stocks, and focused on those issues trading a reasonable valuations relative to their growth rates. Here, the advisors looks at a trio of specialty healthcare companies involved in niche markets such as women's health, autoimmune disease and vaccines. "The Female Health Company (NYSE: FHC) manufactures and markets the female condom. This product currently is the only medical device approved

Alexion's PV system comprises 1,738 photovoltaic solar panels, mounted on the rooftop of the Company's 125,000-square-foot facility in Cheshire, which convert sunlight directly into electricity.

[More...]

Alexion's Soliris® Receives 2009 Prix Galien France for Most Innovative Drug for Rare Disease

Wed, 10 Jun 2009 16:56:00 GMT

Alexion Pharma France and Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today received the 2009 Prix Galien France for Soliris® (eculizumab) in the category of medicines for rare diseases. The award recognizes the scientific innovation represented by the complement-inhibition technology of Soliris, and the impact the drug is having on the lives of patients with paroxysmal nocturnal hemoglobinuria (PNH), an ultra-rare, debilitating and life-threatening blood disorder.[More...]

Alexion to Present at the Jefferies & Co. 3rd Annual Healthcare Conference

Wed, 10 Jun 2009 13:58:00 GMT

Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that Dr. Leonard Bell, Chief Executive Officer of Alexion Pharmaceuticals, will present at the Jefferies & Co. 3rd Annual Healthcare Conference in New York City at 10:15 a.m., ET on Wednesday, June 17, 2009.[More...]

New Research Presented at EHA Congress Shows That Soliris® Significantly Reduced Hemolysis in Never-Transfused Patients with PNH

Sun, 07 Jun 2009 09:41:00 GMT

Clinical investigators observed that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN), reduced hemolysis (red blood cell destruction) and improved symptoms in nine patients with paroxysmal nocturnal hemoglobinuria (PNH) who had received no blood transfusions prior to initiating Soliris therapy.[More...]